Use of recombinant granulocyte-macrophage colony-stimulating factor during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia (AML)

Blood

Volumn 90, Issue 8, 1997, Pages 2952-2961

  Lowenberg B ^a   Suciu, S ^b   Archimbaud, E ^b   Ossenkoppele, G ^b   Verhoef, G E G ^b   Vellenga, E ^b   Wijermans, P ^b   Berneman, Z ^b   Dekker, A W ^b   Stryckmans, P ^b   Schouten, H ^b   Jehn, U ^b   Muus, P ^b   Sonneveld, P ^b   Dardenne, M ^b   Zittoun, R ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN; MOLGRASTIM; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLEEDING; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DIARRHEA; DRUG SENSITIZATION; FEMALE; FEVER; FLUID RETENTION; HUMAN; HYPOTENSION; KIDNEY DISEASE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; TRANSFUSION; TREATMENT OUTCOME; ACUTE DISEASE; DISEASE FREE SURVIVAL; MIDDLE AGED; MULTICENTER STUDY; MYELOID LEUKEMIA; PROGNOSIS; PROSPECTIVE STUDY; REMISSION;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; CYTARABINE; DAUNORUBICIN; DISEASE-FREE SURVIVAL; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; REMISSION INDUCTION;

EID: 0031572528     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Brinker H: Estimate of overall treatment results in acute nonlymphocytic leukemia based on age specific rates of incidence and complete remission. Cancer Treatment Rep 69:5, 1985
2. Brinker H: Population-based age and sex specific incidence rates in the 4 main types of leukemia. Scand J Haemat 29:241, 1989
3. Löwenberg B: Post-remission treatment of acute myelogenous leukemia. N Engl J Med 332:260, 1995 (editorial)
4. Löwenberg B: Treatment of the elderly patient with acute myeloid leukemia, in B. Löwenberg (ed): Acute Myelogenous Leukaemia and Myelodysplasia, Baillière's Clinical Haematology (vol 9). London, UK, Saunders, 1996, p 147
5. Rees JKH, Gray RG, Swirsky D, Hayhoe FGJ: Principal results of the medical research council's 8th acute myeloid leukemia trial. Lancet 2:1236, 1986
6. Rees JKH, Gray R: Comparison of 1 + 5 DAT and 3 + 10 DAT followed by COAP or MAZE consolidation therapy in the treatment of acute myeloid leukemia: MRC ninth AML trial. Sem Oncol 14:32, 1987
7. Löwenberg B, Zittoun R, Kerkhofs H, Jehn U, Abels J, Debusscher L, Cauchie Ch, Peetermans M, Solbu G, Suciu S, Stryckmans P: On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: A randomized phase III study of the EORTC Leukemia Group. J Clin Oncol 1:1268, 1989
8. Arlin Z, Case DC, Moore J, Wiernik P, Feldman E, Saletan S, Desai P, Sia L, Cartwright K, Lederle Cooperative Group: Randomised multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Leukemia 4:177, 1990
9. Liu Yin JA, Johnson PRE, Davies JM, Flanagan NG, Gorst DW, Lewis MJ: Mitoxantrone and cytosine arabinoside as first-line therapy in elderly patients with acute myeloid leukemia. Br J Haematol 79:415, 1991
10. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, Ross Mclntyre O, Frei E, III for the Cancer and Leukemia Group B: Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 331:896, 1994
11. Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman P, Lee EJ, Moore JO, Powell BL, Schiffer CA for the Cancer and Leukemia Group B: Granulocyte-macrophage colonystimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N Engl J Med 332:1671, 1995
12. Dombret H, Chastang C, Fenaux P, Reiffers J, Bordessoule D, Bouabdal lah R, Mandelli F, Ferrant A, Auzanneau G, Tilly H, Yver A, Degos L for the AML Cooperative Study Group: A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. N Engl J Med 332:1678, 1995
13. Bhalla K, Birkhofer M, Arlin Z, Grant S, Lutzky J, Graham G: Effect of recombinant GM-CSF on the metabolism of cytosine arabinoside in normal and leukemic human bone marrow cells. Leukemia 2:810, 1988
14. Cannistra SA, Groshek P, Griffin JD: Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia. Leukemia 3:328, 1989
15. Miyauchi J, Kelleher CA, Wang CH, Minkin S, McCulloch EA: Growth factors influence the sensitivity of leukemic stem cells to cytosine arabinoside in culture. Blood 73:1272, 1989
16. Te Boekhorst PAW, Löwenberg B, Sonneveld P: Stimulation by granulocyte colony stimulating factor (G-CSF), interleukin-3 (IL-3) or granulocyte-macrophage colony stimulating factor (GM-CSF) enhances chemosensitivity by clonogenic acute myeloid leukemia cells. Blood 80:432, 1992
17. Hiddemann W, Kiehl M, Zühlsdorf M, Busermann C, Schleyer E, Wör mann B, Büchner Th: Granulocyte-macrophage colony-stimulating factor and interleukin-3 enhance the incorporation of cytosine arabinoside into the DNA of leukemic blasts and the cytotoxic effect of clonogenic cells from patients with acute myeloid leukemia. Semin Oncol 19:31, 1992
18. Te Boekhorst PAW, Löwenberg B, Sonneveld P: Hematopoietic growth factor stimulation and cytarabine cytotoxicity in vitro: Effects in untreated and relapsed or primary refractory acute myeloid leukemia. Leukemia 8:1480, 1994
19. Kahn SB, Begg CB, Mazza JJ, Bennett JH, Bonner H, Glick JH: Full dose versus attenuated dose daunorubicin, cytosine arabinoside, and 6-thioguanine in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol 2:865, 1984
20. Löwenberg B, Zittoun R, Kerkhofs H, Jehn U, Abels J, Debusscher L, Cauchie Ch, Peetermans M, Solbu G, Suciu S and Stryckmans P: On the value of intensive remission induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: A randomized phase III study of the EORTC Leukemia Group. J Clin Concol 1:1268, 1989
21. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C: Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British group. Ann Int Med 103:620, 1985
22. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C: Proposal for the recognition of minimally differentiated acute myeloid leukemia (AML-M0). Br J Haematol 78:325, 1991
23. Mitelman F(ed): Guidelines for Cancer Cytogenetics. Supplement to An International System for Human Cytogenetic Nomenclature. Basel, Switzerland, S. Karger, 1991
24. Keating MJ, Smith TL, Kantarjian H, Cork A, Walters R, Trujillo JM, McCredie KB, Gehan EA, Freireich EJ: Cytogenetic pattern in acute myelogenous leukemia: A major reproducible determinant of outcome. Leukemia 2:403, 1988
25. Schiffer CA, Lee EJ, Tomiyasu T, Wiernik PH, Testa JR: Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. Blood 73:263, 1989
26. Buyse ME, Staquet MJ, Sylvester RJ (eds): Cancer Clinical Trials: Methods and Practice. Oxford, UK, Oxford University Press, 1992
27. Gardner MJ, Altman DG (eds): Statistics with Confidence-Confidence Intervals and Statistical Guidelines. London, UK, British Medical Journal, 1989
28. Terpstra W, Prins A, Ploemacher RE, Wognum BW, Wagemaker G, Löwenberg B, Wielenga JJ: Long-term leukemia-initiating capacity of CD34-subpopulation of acute myeloid leukemia. Blood 87:2187, 1996
29. Zittoun R, Suciu S, Mandelli F, de Witte Th, Thaler J, Stryckmans P, Hayat M, Peetermans M, Cadiou M, Solbu G, Concetta Petti M, Willemze R: Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. J Clin Oncol 14:2150, 1996
30. Baudard M, Marie JP, Cadiou M, Vignié F, Zittoun R: Acute myelogenous leukemia in the elderly: Retrospective study of 235 consecutive patients. Br J Haematol 86:82, 1994
31. Dastugue N, Payen C, Lafage-Pochilatoff M, Bernard P, Leroux D, Huguet-Rigal F, Stoppa AM, Marit G, Molina L, Michallet M: Prognostic significance of karyotype in de novo adult acute myeloid leukemia. Leukemia 9:1491, 1995
32. Bettelheim P, Valent P, Andreeff M, Tafuri A, Haimi J, Gorischek C, Muhm M, Sillaber S, Haas O, Vieder L, Maurer D, Schulz G, Speiser W, Geissler K, Kier P, Hinterberger W, Lechner K: Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia. Blood 77:700, 1991
33. Büchner Th, Hiddemann W, Koenigsmann M, Zühlsdorf M, Wörmann B, Boeckmann A, Freire E, Innig G, Maschmeyer G, Ludwig W-D, Sauerland M-Ch, Heinecke A, Schulz G: Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse. Blood 78:1190, 1991
34. Ohno R, Naoe T, Kanamaru A, Yoshida M, Hiraoka A, Kobayashi T, Ueda T, Minami S, Morishima Y, Saito Y, Furusawa S, Imai K, Takemoto Y, Miura Y, Teshima H, Hamajima N and the Kohseisho Leukemia Study Group: A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Blood 83:2086, 1994
35. Löwenberg B, Touw IP: Hematopoietic growth factors and their receptors in acute leukemia. Blood 81:281, 1993
36. Rowe JM, Andersen JW, Mazza JJ, Bennett JM, Paietta E, Hayes FA, Oette D, Cassileth PA, Stadtmauer EA, Wiernik PH: A randomized placebo-controlled phase III study of granulocytemacrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group (E 1490). Blood 86:457, 1995
37. Löwenberg B, Suciu S, Archimbaud E, Haak H, Stryckmans P, de Cataldo R, Dekker AW, Berneman ZN, Thyss A, van der Lelie J, Sonneveld P, Visani G, Fillet G, Hayat M, Hagemeijer A, Solbu G, Zittoun R: Mitoxantrone versus Daunorubicine in induction-consolidation chemotherapy, the value of low-dose cytarabine for maintenance of remission as well as an assessment of prognostic factors in acute myeloid leukemia in the elderly: Final report of the EORTC LCG-HOVON randomized phase III study AML-9. J Clin Oncol (in press)